Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ . 38K+ Ratings Google Play and App Store | IFTA Startup of the year 2025 | Forbes Asia Top 100 Startups to Watch 2026 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
Vijaya Diagnostic Centre Raises FY27 EBITDA Margin Guidance to 42%
Vijaya Diagnostic Centre upgraded its FY27 EBITDA margin target to 42% from 40%. Supported by operating leverage and high B2C revenue contribution, the company continues to deliver profitability momentum following a 42.7% EBITDA margin achieved in Q1 FY27.
Steel Exchange India Board Meets For Q2 Results Following Record August Production
Steel Exchange India Limited has released its Q2 financial results alert indicating revenue of ₹343 crore (as stated in the source alert; not independently verified). The update follows operational momentum marked by record August 2026 Re-Bar output of 24,823.51 MT and cumulative debt reduction of ₹86 crore.
Biocon Targets Stronger H2 FY27 Driven By Expanded Insulin Production Capacity
Biocon positions its H1 FY27 operational progress as a launchpad for improved growth in H2 FY27. Management points to commercialization milestones in biosimilars and ramped-up insulin manufacturing capacity to bolster market performance.
